Cargando…

Severe Thrombocytopenia Due to Repaglinide in a Patient With Type 2 Diabetes

Detalles Bibliográficos
Autores principales:	Katsuyama, Hisayuki, Hiraishi, Chika, Hakoshima, Yuki, Yanai, Hidekatsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Online Letters: Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579373/ https://www.ncbi.nlm.nih.gov/pubmed/23431098 http://dx.doi.org/10.2337/dc12-1849

Ejemplares similares

The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat
por: Katsuyama, Hisayuki, et al.
Publicado: (2019)

A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Habit of Bathing or Showering Is Beneficially Associated With Body Weight and Abdominal Circumference in Patients With Type 2 Diabetes
por: Katsuyama, Hisayuki, et al.
Publicado: (2018)

Clinical, Biochemical, Hematological, Endocrinological and Immunological Differences Between Graves’ Disease Patients With and Without Thyroid Storm
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Streptococcal Infection Can Be the Trigger for Thyroid Storm
por: Hakoshima, Mariko, et al.
Publicado: (2019)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors
por: Katsuyama, Hisayuki, et al.
Publicado: (2016)

Habitual Hot-Tub Bathing and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2022)

Clinical, Hematological, Biochemical and Radiological Characteristics for Patients With Splenic Infarction: Case Series With Literature Review
por: Hakoshima, Mariko, et al.
Publicado: (2023)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Exercise Therapy for Patients With Type 2 Diabetes: A Narrative Review
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

Comment on: Tsiakou et al. Arterial Stiffness Is Inversely Related to Plasma Adiponectin Levels in Young Normotensive Patients With Type 1 Diabetes. Diabetes Care 2013;36:734–736
por: Hamasaki, Hidetaka, et al.
Publicado: (2013)

Long-Term Effect of an Education Program (HyPOS) on the Incidence of Severe Hypoglycemia in Patients With Type 1 Diabetes
por: Hermanns, Norbert, et al.
Publicado: (2010)

Diabetic Hepatosclerosis Presenting With Severe Cholestasis
por: Nazzari, Elena, et al.
Publicado: (2013)

Does Metformin Assist New Anti-Diabetic Drugs to Succeed?
por: Kastuyama, Hisayuki, et al.
Publicado: (2019)

Association of handgrip strength with hospitalization, cardiovascular events, and mortality in Japanese patients with type 2 diabetes
por: Hamasaki, Hidetaka, et al.
Publicado: (2017)

Severe Hypercalcemia in Diabetic Ketoacidosis: A Case Report
por: Makaya, Tafadzwa, et al.
Publicado: (2013)

What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

Assessment of Emotional Struggles in Type 2 Diabetes: Patient Perspectives
por: Beverly, Elizabeth A., et al.
Publicado: (2012)

Glucose-6-Phosphate Dehydrogenase Deficiency and Type 2 Diabetes
por: Heymann, Anthony D., et al.
Publicado: (2012)

Ketosis-Prone Type 2 Diabetes in a Veteran Population
por: Goodstein, Gelsey, et al.
Publicado: (2014)

Screening Patients With Type 2 Diabetes for Active Tuberculosis in Communities of China
por: Zhao, Wenjing, et al.
Publicado: (2013)

Dietary Quality in Adolescents With Type 1 Diabetes
por: Bansal, Nidhi, et al.
Publicado: (2013)

No Relation Between Cystic Fibrosis–Related Diabetes and Type 1 Diabetes Autoimmunity
por: Gottlieb, Peter A., et al.
Publicado: (2012)

Which Factor Determines the Duration Required for Relief of Glucotoxicity by the Intensive Insulin Therapy?
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d015ubg8iuihb8icmfvrck6f8t